⌕
Sana Biotechnology · SANA · Nasdaq
$1.8815-min delayed· as of Nov 17, 2026Tenet 36 · Weak
Compare
$1.8815-min delayedTenet 36 · Weak

Sana Biotechnology (SANA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

16 figures withheld by our checks. Each blank figure names its reason.

Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+52.2%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▲8.5%
−244.2
FY21→FY25CAGR —
Free cash flow ($M)▲43.6%
−144.8
FY21→FY25CAGR —
Diluted EPS▲17.2%
−0.96
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+52.2%

166.4mn → 253.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$938.0K

−97.2% YoY in FY25.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−161.4R&D−44.3SG&A−250.3Op income6.2Tax & other−244.2Net income

Margin trend · direction beats level
108530%sector median net margin ~3%FY21FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.00.00.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.00.00.0——
Research & development
111,358.0161,412.0206,792.0212,828.0201,003.0306,499.0▼21.9%−14.8%
Selling, general & admin
45,369.044,296.064,040.073,299.071,561.050,410.0▼30.8%−3.2%
Total operating expenses
156,727.0250,319.0272,723.0293,141.0272,564.0356,909.0▼8.2%−8.5%
Operating incomefeeds ROC rank
−156,727.0−250,319.0−272,723.0−293,141.0−272,564.0−356,909.0▲8.2%—
Other income, net
5,153.03,848.05,964.09,886.03,088.0981.0——
Pretax income
−151,574.0−246,471.0−266,759.0−283,255.0−269,476.0−355,928.0▲7.6%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−149,269.0−244,166.0−266,759.0−283,255.0−269,476.0−355,928.0▲8.5%—
Per share
Diluted EPSbuyback-sensitive
−0.52−0.96−1.16−1.46−1.43−2.14▲17.2%—
Diluted shares (mn)
308.79253.23230.89194.54188.34166.43▲9.7%+11.1%
Margins
† TTM = trailing four quarters through 2026-09-30.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-03 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.